止血剤の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2024～2032年）

止血剤市場の世界需要は、2023年の31億1,000万米ドルから、2032年までには約59億9,000万米ドルの市場規模に達すると推定され、調査期間の2024年から2032年のCAGRは7.56%です。

止血剤は、血栓形成を促進し出血を止めることによって出血をコントロールするために使用される物質です。これらの薬剤には、傷口に直接塗布する局所止血剤や、出血性疾患や外科的出血を管理するために静脈内投与する全身性薬剤が含まれます。止血剤は、過剰な出血を防ぎ、組織の治癒を促進するため、様々な医療処置、外傷治療、手術において極めて重要です。

市場力学

世界の外科手術、外傷、心臓血管手術の増加により、出血を効果的にコントロールし、手術中や手術後の合併症のリスクを軽減する止血剤の需要が高まっています。止血剤は、止血を達成し、過剰な出血を防ぎ、患者の転帰を改善する上で重要な役割を果たすため、一般外科、整形外科、神経外科、外傷治療など、さまざまな診療科で採用が進んでいます。また、天然素材や合成素材由来の生体適合性・生分解性止血剤の開発など、止血技術の進歩により、その安全性プロファイルと有効性が向上し、医療従事者や患者への市場浸透と受容が促進されています。さらに、高齢者人口の拡大や、心血管障害やがんなどの慢性疾患の負担増が、市場の成長を高めています。

さらに、救急医療、軍用ヘルスケア、スポーツ医学など、従来の外科手術以外の場面でも止血剤の用途が拡大していることが市場の可能性を広げ、止血剤市場の技術革新と製品開拓を促進しています。有利な規制状況、医療費の増加、医療研究開発への投資の増加は、市場の成長を維持し、市場のイノベーションを促進し、アンメット・クリニカル・ニーズに対応し、世界の医療現場における患者のケアを強化すると期待されています。しかし、止血剤に含まれる特定の成分の使用に関する規制上の監視や安全性への懸念の高まり、代替止血技術の出現は、市場成長の妨げになる可能性が高いです。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは止血剤の世界市場における各セグメントを包括的に評価することもできます。止血剤産業の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

止血剤市場レポートのこのセクションでは、国別および地域別のセグメントに関する詳細なデータを提供することで、戦略担当者がそれぞれの製品またはサービスのターゲット層を特定し、今後のビジネスチャンスに役立てることができます。

製品タイプ別

• 活性剤
• 受動剤
• 配合剤

専門分野/治療領域別

• 循環器
• カテーテル検査
• 外傷
• 一般外科
• 産婦人科
• 移植
• 腫瘍学
• 神経学
• 整形外科
• 形成外科
• 歯科
• その他（泌尿器外科、呼吸器外科）

流通チャネル別

• 大規模病院（500床以上）
• 中規模病院（250～499床）
• 小規模病院（250床以下）

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける止血剤市場の現在および将来の需要を強調する地域展望をカバーします。さらに、著名な全地域における個々の用途セグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

• 市場のハイライト
• 世界市場スナップショット

第3章 止血剤 - 産業分析

• イントロダクション：市場力学
• 市場促進要因
• 市場抑制要因
• 機会
• 業界動向
• ポーターのファイブフォース分析
• 市場魅力度分析

第4章 バリューチェーン分析

• バリューチェーン分析
• 原材料分析
  • 原材料リスト
  • 原材料メーカーリスト
  • 主要原材料の価格動向
• 潜在的バイヤーのリスト
• マーケティングチャネル
  • ダイレクトマーケティング
  • インダイレクトマーケティング
  • マーケティングチャネル発展動向

第5章 止血剤の世界市場分析：製品タイプ別

• 概要：製品タイプ別
• 実績データと予測データ
• 分析：製品タイプ別
• 活性剤
• パッシブ剤
• 配合剤

第6章 止血剤の世界市場分析：専門分野/治療領域別

• 概要：専門分野/治療領域別
• 実績データと予測データ
• 分析：専門分野/治療領域別
• 循環器内科
• カテーテル検査
• 外傷
• 一般外科
• 産婦人科
• 移植
• 腫瘍学
• 神経学
• 整形外科
• 形成外科
• 歯科

第7章 止血剤の世界市場分析：流通チャネル別

• 概要：：流通チャネル別
• 実績データと予測データ
• 分析：流通チャネル別
• 大規模病院（500床以上）
• 中規模病院（250～499床）
• 小規模病院（250床以下）

第8章 止血剤の世界市場分析：地域別

• 地域別展望
• イントロダクション
• 北米の売上分析
  • 概要、実績と予測
  • 北米：セグメント別
  • 北米：国別
  • 米国
  • カナダ
  • メキシコ
• 欧州の売上分析
  • 概要、実績と予測
  • 欧州：セグメント別
  • 欧州：国別
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • ロシア
  • その他欧州
• アジア太平洋の売上分析
  • 概要、実績と予測
  • アジア太平洋：セグメント別
  • アジア太平洋：国別
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • 東南アジア
  • その他アジア太平洋
• ラテンアメリカの売上分析
  • 概要、実績と予測
  • ラテンアメリカ：セグメント別
  • ラテンアメリカ：国別
  • ブラジル
  • アルゼンチン
  • ペルー
  • チリ
  • その他ラテンアメリカ
• 中東・アフリカの売上分析
  • 概要、実績と予測
  • 中東・アフリカ：セグメント別
  • 中東・アフリカ：国別
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他中東・アフリカ

第9章 止血剤企業の競合情勢

• 止血剤の市場競合
• 提携/協力/合意
• 合併・買収
• 新製品の上市
• その他の開発

第10章 企業プロファイル

• 企業シェア分析
• 市場集中度
• Baxter
• Ethicon Inc.
• BD
• B. Braun SE
• Pfizer Inc.
• Teleflex Incorporated
• CryoLife Inc.
• Integra LifeSciences
• Advanced Medical Solutions Group plc
• Gelita AG

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Product Type (USD MN)
• Active Agents Market Sales by Geography (USD MN)
• Passive Agents Market Sales by Geography (USD MN)
• Combination Market Sales by Geography (USD MN)
• Analysis Market by Specialty / Therapeutic Area (USD MN)
• Cardiology Market Sales by Geography (USD MN)
• Cath Lab Market Sales by Geography (USD MN)
• Trauma Market Sales by Geography (USD MN)
• General Surgery Market Sales by Geography (USD MN)
• ObGyn Market Sales by Geography (USD MN)
• Transplant Market Sales by Geography (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Neurology Market Sales by Geography (USD MN)
• Orthopedic Market Sales by Geography (USD MN)
• Plastic Surgery Market Sales by Geography (USD MN)
• Dental Market Sales by Geography (USD MN)
• Analysis by Distribution Channel (USD MN)
• Large Hospital (500+ Beds) Market Sales by Geography (USD MN)
• Medium Hospital (250-499 Beds) Market Sales by Geography (USD MN)
• Small Hospitals (Less than 250 Beds) Market Sales by Geography (USD MN)
• Global Hemostatic Agents Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Hemostatic Agents Report
• Market Research Process
• Market Research Methodology
• Global Hemostatic Agents Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Product Type
• Market Attractiveness Analysis by Specialty / Therapeutic Area
• Market Attractiveness Analysis by Distribution Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Product Type (USD MN)
• Active Agents Market Sales by Geography (USD MN)
• Passive Agents Market Sales by Geography (USD MN)
• Combination Market Sales by Geography (USD MN)
• Global Market Analysis by Specialty / Therapeutic Area (USD MN)
• Cardiology Market Sales by Geography (USD MN)
• Cath Lab Market Sales by Geography (USD MN)
• Trauma Market Sales by Geography (USD MN)
• General Surgery Market Sales by Geography (USD MN)
• ObGyn Market Sales by Geography (USD MN)
• Transplant Market Sales by Geography (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Neurology Market Sales by Geography (USD MN)
• Orthopedic Market Sales by Geography (USD MN)
• Plastic Surgery Market Sales by Geography (USD MN)
• Dental Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution Channel (USD MN)
• Large Hospital (500+ Beds) Market Sales by Geography (USD MN)
• Medium Hospital (250-499 Beds) Market Sales by Geography (USD MN)
• Small Hospitals (Less than 250 Beds) Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

The global demand for Hemostatic Agents Market is presumed to reach the market size of nearly USD 5.99 Billion by 2032 from USD 3.11 Billion in 2023 with a CAGR of 7.56% under the study period 2024 - 2032.

Hemostatic agents are substances used to control bleeding by promoting clot formation and stopping hemorrhage. These agents may include topical hemostatic agents applied directly to wounds and systemic medications administered intravenously to manage bleeding disorders or surgical bleeding. They are crucial in various medical procedures, trauma care, and surgery to prevent excessive blood loss and promote tissue healing.

MARKET DYNAMICS

The increasing incidence of surgical procedures, trauma cases, and cardiovascular surgeries worldwide has fueled the demand for hemostatic agents that effectively control bleeding and mitigate the risk of complications during and after surgery. Hemostatic agents play a crucial role in achieving hemostasis, preventing excessive blood loss, and improving patient outcomes, driving their adoption across diverse medical specialties, including general surgery, orthopedics, neurosurgery, and trauma care. Additionally, advancements in hemostatic technologies, such as developing biocompatible and biodegradable hemostatic agents derived from natural or synthetic materials, have enhanced their safety profile and efficacy, propelling market penetration and acceptance among healthcare professionals and patients. Furthermore, the expanding geriatric population and the escalating burden of chronic diseases, such as cardiovascular disorders and cancer, have increased market growth.

Furthermore, the expanding applications of hemostatic agents beyond traditional surgical settings, including emergency medical services, military healthcare, and sports medicine, have broadened their market potential, driving innovation and product development in the hemostatic agents market. Favorable regulatory frameworks, increasing healthcare expenditure, and growing investments in medical research and development are expected to sustain market growth and thrive in market innovation, addressing unmet clinical needs and enhancing patient care in the global healthcare landscape. However, increasing regulatory scrutiny and safety concerns regarding using certain ingredients in hemostatic agents and the emergence of alternative hemostatic technologies likely hamper market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of hemostatic agents. The growth and trends of hemostatic agents industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the hemostatic agents market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

• Active Agents
• Passive Agents
• Combination

By Specialty / Therapeutic Area

• Cardiology
• Cath Lab
• Trauma
• General Surgery
• Obgyn
• Transplant
• Oncology
• Neurology
• Orthopedic
• Plastic Surgery
• Dental
• Others (Urological Surgeries, Pulmonary Surgeries)

By Distribution Channel

• Large Hospital (500+ Beds)
• Medium Hospital (250-499 Beds)
• Small Hospitals (Less Than 250 Beds)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Hemostatic Agents market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Hemostatic Agents market include Baxter, Ethicon, Inc., BD, B. Braun SE, Pfizer, Inc., Teleflex Incorporated, CryoLife, Inc., Integra LifeSciences, Advanced Medical Solutions Group plc, Gelita AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . HEMOSTATIC AGENTS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product Type
  • 3.7.2 Market Attractiveness Analysis By Specialty / Therapeutic Area
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL HEMOSTATIC AGENTS MARKET ANALYSIS BY PRODUCT TYPE

• 5.1 Overview by Product Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Product Type
• 5.4 Active Agents Historic and Forecast Sales by Regions
• 5.5 Passive Agents Historic and Forecast Sales by Regions
• 5.6 Combination Historic and Forecast Sales by Regions

6 . GLOBAL HEMOSTATIC AGENTS MARKET ANALYSIS BY SPECIALTY / THERAPEUTIC AREA

• 6.1 Overview by Specialty / Therapeutic Area
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Specialty / Therapeutic Area
• 6.4 Cardiology Historic and Forecast Sales by Regions
• 6.5 Cath Lab Historic and Forecast Sales by Regions
• 6.6 Trauma Historic and Forecast Sales by Regions
• 6.7 General Surgery Historic and Forecast Sales by Regions
• 6.8 ObGyn Historic and Forecast Sales by Regions
• 6.9 Transplant Historic and Forecast Sales by Regions
• 6.10. Oncology Historic and Forecast Sales by Regions
• 6.11 Neurology Historic and Forecast Sales by Regions
• 6.12 Orthopedic Historic and Forecast Sales by Regions
• 6.13 Plastic Surgery Historic and Forecast Sales by Regions
• 6.14 Dental Historic and Forecast Sales by Regions

7 . GLOBAL HEMOSTATIC AGENTS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1 Overview by Distribution Channel
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Distribution Channel
• 7.4 Large Hospital (500+ Beds) Historic and Forecast Sales by Regions
• 7.5 Medium Hospital (250-499 Beds) Historic and Forecast Sales by Regions
• 7.6 Small Hospitals (Less than 250 Beds) Historic and Forecast Sales by Regions

8 . GLOBAL HEMOSTATIC AGENTS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE HEMOSTATIC AGENTS COMPANIES

• 9.1. Hemostatic Agents Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF HEMOSTATIC AGENTS INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Baxter
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Ethicon Inc.
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. BD
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. B. Braun SE
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Pfizer Inc.
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Teleflex Incorporated
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. CryoLife Inc.
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Integra LifeSciences
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Advanced Medical Solutions Group plc
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Gelita AG
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies